Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9844 |
High Similarity |
NPD230 |
Phase 1 |
0.8984 |
High Similarity |
NPD9269 |
Phase 2 |
0.8672 |
High Similarity |
NPD9268 |
Approved |
0.8523 |
High Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.845 |
Intermediate Similarity |
NPD9545 |
Approved |
0.8392 |
Intermediate Similarity |
NPD6190 |
Approved |
0.8158 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8146 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8146 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8102 |
Intermediate Similarity |
NPD9494 |
Approved |
0.8079 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8071 |
Intermediate Similarity |
NPD943 |
Approved |
0.8056 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8027 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7974 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7973 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7973 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7973 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7972 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7919 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7908 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7888 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7857 |
Intermediate Similarity |
NPD5353 |
Approved |
0.7812 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7785 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7785 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7762 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7748 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7703 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7688 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7688 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7688 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7683 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7676 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7654 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7654 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7643 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.764 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7619 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7612 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7607 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7607 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7606 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7603 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7597 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7597 |
Intermediate Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.7595 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7584 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7569 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7564 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7564 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7561 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7552 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7551 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7551 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.755 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7532 |
Intermediate Similarity |
NPD3455 |
Phase 2 |
0.7516 |
Intermediate Similarity |
NPD5242 |
Approved |
0.7515 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7515 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.75 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7484 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7468 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7467 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7467 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7466 |
Intermediate Similarity |
NPD1607 |
Approved |
0.745 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7436 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7436 |
Intermediate Similarity |
NPD6385 |
Approved |
0.7436 |
Intermediate Similarity |
NPD6386 |
Approved |
0.7429 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7421 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7405 |
Intermediate Similarity |
NPD5402 |
Approved |
0.74 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7389 |
Intermediate Similarity |
NPD37 |
Approved |
0.7383 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7383 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7358 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7358 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7358 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7351 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7315 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7273 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7267 |
Intermediate Similarity |
NPD919 |
Approved |
0.725 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7248 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7239 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7239 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7235 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7234 |
Intermediate Similarity |
NPD9717 |
Approved |
0.7222 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7211 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7211 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7211 |
Intermediate Similarity |
NPD825 |
Approved |
0.7211 |
Intermediate Similarity |
NPD826 |
Approved |
0.7179 |
Intermediate Similarity |
NPD920 |
Approved |
0.7179 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7178 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7172 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7163 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7161 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7133 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7113 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7101 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7099 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7097 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7091 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7081 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD411 |
Approved |
0.7073 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7073 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7059 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7051 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7051 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7051 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD555 |
Phase 2 |
0.7047 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7041 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7024 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7024 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7021 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7015 |
Intermediate Similarity |
NPD2182 |
Approved |
0.7015 |
Intermediate Similarity |
NPD9266 |
Approved |
0.7015 |
Intermediate Similarity |
NPD74 |
Approved |
0.7011 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD6651 |
Approved |
0.6988 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6987 |
Remote Similarity |
NPD7390 |
Discontinued |
0.6985 |
Remote Similarity |
NPD228 |
Approved |
0.6981 |
Remote Similarity |
NPD824 |
Approved |
0.6974 |
Remote Similarity |
NPD9570 |
Approved |
0.6974 |
Remote Similarity |
NPD6100 |
Approved |
0.6974 |
Remote Similarity |
NPD6099 |
Approved |
0.6943 |
Remote Similarity |
NPD3146 |
Approved |
0.6943 |
Remote Similarity |
NPD3688 |
Clinical (unspecified phase) |
0.694 |
Remote Similarity |
NPD9263 |
Approved |
0.694 |
Remote Similarity |
NPD1358 |
Approved |
0.694 |
Remote Similarity |
NPD9267 |
Approved |
0.694 |
Remote Similarity |
NPD9264 |
Approved |
0.6939 |
Remote Similarity |
NPD6832 |
Phase 2 |
0.6933 |
Remote Similarity |
NPD1933 |
Approved |
0.6929 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6923 |
Remote Similarity |
NPD643 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD257 |
Approved |
0.6918 |
Remote Similarity |
NPD1019 |
Discontinued |
0.6918 |
Remote Similarity |
NPD258 |
Approved |
0.6913 |
Remote Similarity |
NPD259 |
Phase 1 |
0.6913 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6908 |
Remote Similarity |
NPD2799 |
Discontinued |
0.6901 |
Remote Similarity |
NPD17 |
Approved |
0.6897 |
Remote Similarity |
NPD8150 |
Discontinued |
0.689 |
Remote Similarity |
NPD6971 |
Discontinued |
0.6879 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD3226 |
Approved |
0.6866 |
Remote Similarity |
NPD3134 |
Approved |
0.6863 |
Remote Similarity |
NPD5404 |
Approved |
0.6863 |
Remote Similarity |
NPD5406 |
Approved |
0.6863 |
Remote Similarity |
NPD5408 |
Approved |
0.6863 |
Remote Similarity |
NPD5405 |
Approved |
0.6853 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6839 |
Remote Similarity |
NPD2654 |
Approved |
0.6839 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6838 |
Remote Similarity |
NPD3021 |
Approved |
0.6838 |
Remote Similarity |
NPD3022 |
Approved |
0.6836 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6831 |
Remote Similarity |
NPD4196 |
Clinical (unspecified phase) |
0.6828 |
Remote Similarity |
NPD2982 |
Phase 2 |
0.6828 |
Remote Similarity |
NPD2983 |
Phase 2 |
0.6826 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.681 |
Remote Similarity |
NPD1006 |
Clinical (unspecified phase) |
0.6806 |
Remote Similarity |
NPD3705 |
Approved |
0.6802 |
Remote Similarity |
NPD7240 |
Approved |
0.6802 |
Remote Similarity |
NPD7038 |
Approved |
0.6802 |
Remote Similarity |
NPD7039 |
Approved |
0.6797 |
Remote Similarity |
NPD4308 |
Phase 3 |
0.6795 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6795 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.679 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.6788 |
Remote Similarity |
NPD2181 |
Clinical (unspecified phase) |
0.6781 |
Remote Similarity |
NPD3225 |
Approved |
0.6776 |
Remote Similarity |
NPD6653 |
Approved |
0.677 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6765 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6763 |
Remote Similarity |
NPD1241 |
Discontinued |
0.6759 |
Remote Similarity |
NPD2981 |
Phase 2 |
0.6759 |
Remote Similarity |
NPD3972 |
Approved |
0.6759 |
Remote Similarity |
NPD1481 |
Phase 2 |
0.6757 |
Remote Similarity |
NPD3018 |
Phase 2 |
0.6757 |
Remote Similarity |
NPD9569 |
Approved |
0.6752 |
Remote Similarity |
NPD2354 |
Approved |
0.6752 |
Remote Similarity |
NPD2219 |
Phase 1 |
0.6742 |
Remote Similarity |
NPD1242 |
Phase 1 |
0.6735
|
Remote Similarity |
NPD2797 |
Approved |